INCY - IncyteEPS of $0.10 revenue of $862.5M beats by $49.12M

Incyte press release (NASDAQ:INCY): Q4 EPS of $0.10 may not be comparable to consensus of $0.86. Revenue of $862.5M (+9.2% Y/Y) beats by $49.12M. Total product and royalty revenues of $813 million (+20%) in Q4’21 Jakafi® (ruxolitinib) net product revenues of $592 million (+15%) in Q4’21 and $2.135 billion (+10%) in FY’21; Jakafi guidance range of $2.3 to $2.4 billion for 2022. The company expects other Hematology/Oncology net product revenue of $210M-$240M The company expects Non-GAAP R&D expenses of $1.42B-$1.46B The company expects Non-GAAP SG&A expenses of $880M-$925M.

For further details see:

IncyteEPS of $0.10, revenue of $862.5M beats by $49.12M